Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial
1998

Tamoxifen and Hormone Replacement Therapy Effects on Heart Health

Sample size: 2925 publication Evidence: moderate

Author Information

Author(s): A Decensi, C Robertson, N Rotmensz, G Seven, P Maisonneuve, V Sacchini, P Boyle, A Costal, U Veronesi

Primary Institution: European Institute of Oncology

Hypothesis

Does the combination of tamoxifen and hormone replacement therapy affect cardiovascular risk factors?

Conclusion

Tamoxifen's beneficial effects on cardiovascular risk factors are maintained in women already using hormone replacement therapy, but may be reduced in those who start hormone therapy during tamoxifen treatment.

Supporting Evidence

  • Tamoxifen reduced total cholesterol by approximately 9% in both HRT users and non-users.
  • The reduction in LDL cholesterol was similar across both groups.
  • Women who started HRT during tamoxifen treatment experienced a reduced effect on cholesterol levels.

Takeaway

This study looked at how a medicine for breast cancer and hormone therapy work together. It found that if women were already using hormone therapy, the breast cancer medicine still worked well, but starting hormone therapy while on the medicine might make it less effective.

Methodology

The study involved a prevention trial where women were randomized to receive either tamoxifen or placebo, with blood measurements taken at baseline and 12 months.

Potential Biases

Women on HRT may have been selected based on higher cholesterol levels, potentially skewing results.

Limitations

The study was observational and not randomized for HRT use, which may introduce selection bias.

Participant Demographics

Women aged 35 to 70, with a history of hysterectomy for non-malignant conditions.

Statistical Information

P-Value

0.051

Statistical Significance

p=0.051

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication